Literature DB >> 27120357

Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.

Yoon Seong Choi1, Sung Soo Ahn1, Dong Wook Kim1, Jong Hee Chang1, Seok-Gu Kang1, Eui Hyun Kim1, Se Hoon Kim1, Tyler Hyungtaek Rim1, Seung-Koo Lee1.   

Abstract

Purpose To investigate the incremental prognostic value of apparent diffusion coefficient (ADC) histogram analysis over oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in patients with glioblastoma and the correlation between ADC parameters and MGMT status. Materials and Methods This retrospective study was approved by institutional review board, and informed consent was waived. A total of 112 patients with glioblastoma were divided into training (74 patients) and test (38 patients) sets. Overall survival (OS) and progression-free survival (PFS) was analyzed with ADC parameters, MGMT status, and other clinical factors. Multivariate Cox regression models with and without ADC parameters were constructed. Model performance was assessed with c index and receiver operating characteristic curve analyses for 12- and 16-month OS and 12-month PFS in the training set and validated in the test set. ADC parameters were compared according to MGMT status for the entire cohort. Results By using ADC parameters, the c indices and diagnostic accuracies for 12- and 16-month OS and 12-month PFS in the models showed significant improvement, with the exception of c indices in the models for PFS (P < .05 for all) in the training set. In the test set, the diagnostic accuracy was improved by using ADC parameters and was significant, with the 25th and 50th percentiles of ADC for 16-month OS (P = .040 and P = .047) and the 25th percentile of ADC for 12-month PFS (P = .026). No significant correlation was found between ADC parameters and MGMT status. Conclusion ADC histogram analysis had incremental prognostic value over MGMT promoter methylation status in patients with glioblastoma. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27120357     DOI: 10.1148/radiol.2016151913

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

1.  Whole-tumor histogram analysis of DWI and QSI for differentiating between meningioma and schwannoma: a pilot study.

Authors:  Hitomi Nagano; Koji Sakai; Jun Tazoe; Masashi Yasuike; Kentaro Akazawa; Kei Yamada
Journal:  Jpn J Radiol       Date:  2019-08-08       Impact factor: 2.374

2.  Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.

Authors:  Yi Cui; Shangjie Ren; Khin Khin Tha; Jia Wu; Hiroki Shirato; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-02-06       Impact factor: 5.315

3.  The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter.

Authors:  Y S Choi; S S Ahn; H-J Lee; J H Chang; S-G Kang; E H Kim; S H Kim; S-K Lee
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-22       Impact factor: 3.825

4.  Differentiation of intracranial solitary fibrous tumor/hemangiopericytoma from atypical meningioma using apparent diffusion coefficient histogram analysis.

Authors:  Xianwang Liu; Juan Deng; Qiu Sun; Caiqiang Xue; Shenglin Li; Qing Zhou; Xiaoyu Huang; Hong Liu; Junlin Zhou
Journal:  Neurosurg Rev       Date:  2022-03-18       Impact factor: 3.042

Review 5.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

6.  Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.

Authors:  Marianne Schell; Irada Pflüger; Gianluca Brugnara; Fabian Isensee; Ulf Neuberger; Martha Foltyn; Tobias Kessler; Felix Sahm; Antje Wick; Martha Nowosielski; Sabine Heiland; Michael Weller; Michael Platten; Klaus H Maier-Hein; Andreas Von Deimling; Martin J Van Den Bent; Thierry Gorlia; Wolfgang Wick; Martin Bendszus; Philipp Kickingereder
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

7.  Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.

Authors:  Chae Jung Park; Yoon Seong Choi; Yae Won Park; Sung Soo Ahn; Seok-Gu Kang; Jong-Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  Neuroradiology       Date:  2019-12-09       Impact factor: 2.804

8.  MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.

Authors:  H J Choi; S H Choi; S-H You; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn; C-K Park; S-H Park
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

9.  Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.

Authors:  Daniel Paech; Johannes Windschuh; Johanna Oberhollenzer; Constantin Dreher; Felix Sahm; Jan-Eric Meissner; Steffen Goerke; Patrick Schuenke; Moritz Zaiss; Sebastian Regnery; Sebastian Bickelhaupt; Philipp Bäumer; Martin Bendszus; Wolfgang Wick; Andreas Unterberg; Peter Bachert; Mark Edward Ladd; Heinz-Peter Schlemmer; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 13.029

10.  Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

Authors:  Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.